抗糖尿病药物的&ldquo;肠道机制&rdquo;

冯雨薇1; 张烽2; 3; 1; 王雪松3; 4; 1; 夏艳萍2; 3; 华皎5; 1; 曹宏1; 2; 3; 6

doi:10.3969/j.issn.1673-6184.2021.01.009

PDF(817 KB)

微生物与感染 ›› 2021, Vol. 16 ›› Issue (1) : 63-70. DOI: 10.3969/j.issn.1673-6184.2021.01.009

综述

抗糖尿病药物的“肠道机制”

冯雨薇¹，张烽^2，3，1，王雪松^3，4，1，夏艳萍^2，3，华皎^5，1，曹宏^{1，2，3，6}

作者信息 +

The “intestinal mechanism” of anti-diabetes drugs

FENG Yuwei¹, ZHANG Feng^2，3，1, WANG Xuesong^3，4，1, XIA Yanping^2，3, HUA Jiao^5，1, CAO Hong^{1，2，3，6}

Author information +

文章历史 +

摘要

糖尿病已经成为困扰国民的健康问题之一。越来越多的证据表明，肠道菌群与2型糖尿病的发生、发展密切相关。近年来，治疗糖尿病的药物与肠道菌群的关系也引起人们的关注，2型糖尿病药物可以通过调节肠道菌群产生有益的代谢产物与宿主进行“分子对话”，调节机体的糖脂代谢等而达到降血糖的作用。本综述将近年来发表于国内外期刊的与抗糖药物“肠道机制”相关的论文进行归纳、分析与总结，旨在为研究抗糖尿病药物的作用机制提供新的思路，也为完善以肠道菌群为靶点的药物干预方案提供理论依据。

Abstract

Diabetes is one of the most serious public health problems in China. Recently, growing evidence demonstrated that gut microbiota are closely involved in the onset and development of type 2 diabetes. Studies also indicated that anti-diabetic drugs can achieve the effect of lowering blood glucose by modulating gut microbiota to carry out “molecular dialogue” with the host. This paper summarized the recent publications related to the intestinal mechanism of anti-diabetic drugs.

导出引用

冯雨薇1，张烽2，3，1，王雪松3，4，1，夏艳萍2，3，华皎5，1，曹宏1，2，3，6. 抗糖尿病药物的“肠道机制”[J]. 微生物与感染. 2021, 16(1): 63-70 https://doi.org/10.3969/j.issn.1673-6184.2021.01.009

FENG Yuwei1, ZHANG Feng2，3，1, WANG Xuesong3，4，1, XIA Yanping2，3, HUA Jiao5，1, CAO Hong1，2，3，6. The “intestinal mechanism” of anti-diabetes drugs[J]. Journal of Microbes and Infections. 2021, 16(1): 63-70 https://doi.org/10.3969/j.issn.1673-6184.2021.01.009

中图分类号： R378